RGA study highlights potential of incretin-based therapies to improve global health outcomes
Reinsurance News - Nov 13, 2025
Reinsurance Group of America, Incorporated, a provider of life and health reinsurance solutions, has released new research that evaluates the potential effects of incretin-based therapies, including GLP-1 medications, on mortality and morbidity. These drugs, used for both weight management and diabe...
Recommended Articles
Posted: Apr 16, 2026
Capgemini Research Institute, the research division of the Capgemini, has published the report Physi...
Posted: Apr 16, 2026
Beazley, a large specialist insurer, has announced plans to establish a new Marine War insurance con...
Posted: Apr 16, 2026
John Doyle, President and Chief Executive Officer (CEO) of global insurance and reinsurance broking...